Table 1.
Patients clinical characteristics and acute clinical outcome
| Group 2019 162 patients |
Group 2020 84 patients |
P value | Group I 2019 162 patients |
Group II 2020 84 patients |
P value | ||
|---|---|---|---|---|---|---|---|
| AGE | 69.9 + 32.6 | 68.3 + 30.9 | ns | STEMI | 59 (36.4%) | 34 (40.5%) | ns |
| SEX | M:113/F:49 | M:62/F:22 | ns | STEMI rr > 24 hours | 7 (4.3%) | 15 (17.8%) | < 0.001 |
| COPD | 35 (21.6%) | 7 (8.3%) | < 0.01 | NSTEMI | 93 (57.4%) | 33 (39.3%) | < 0.01 |
| HYPERTENSION | 108 (66.7%) | 65 (77.4%) | ns | Others ACS | 3 (1.9%) | 2 (2.4%) | < 0.01 |
| DIABETES | 48 (29.6%) | 31 (36.9%) | ns | Door to balloon (STEMI) | 40 + 12 (minutes) | 66 + 17 (minutes) | < 0.001 |
| SMOKING | 85 (52.5%) | 34 (40.5%) | ns | Symptoms to PCI (STEMI) | 3.9 + 2.2 (hours) | 5.8 + 3.1 (hours) | < 0.001 |
| DYSLIPIDEMIA | 100 (61.7%) | 58 (69%) | ns | Symptoms to PCI (NSTEMI) | 18.8 + 20 (hours) | 36.9 + 38.4 (hours) | < 0.001 |
| BMI > 30 | 36 (22.2%) | 23 (27.4%) | ns | hs-cTnI (basal) | 1142 + 4017 | 5138 + 9408 | < 0.001 |
| KNOWN CAD | 41 (25.3%) | 31 (36.9%) | ns | hs-cTnI (peak) | 9143 + 13,825 | 13,681 + 10,936 | < 0.01 |
| AF | 18 (11.1%) | 6 (7.1%) | ns | LVEF | 48.9 + 9.4 | 45.9 + 12 | < 0.05 |
| CKD | 21 (13%) | 12 (14.3%) | ns | LVEF < 40% | 24.7% | 42.8% | < 0.01 |
| GRACE SCORE | 116 + 26 | 126 + 27 | < 0.01 | Death | 1.8% | 4.7% | ns |
Other ACS (Tako-Tsubo syndrome or myocardial infarction with nonobstructive coronary arteries [MINOCA]).
AF, atrial fibrillation; ACS, acute coronary syndrome; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; GRACE, Global Registry of Acute Coronary Events; hs-cTnI, high-sensitivity cardiac troponin I (lab range 0-58 ng/L); LVEF, left-ventricular ejection fraction; NSTEMI, non–ST-elevation myocardial infarction; rr, recommended reperfusion; PCI, percutaneous coronary intervention; rr, recommended reperfusion; STEMI, ST-elevation myocardial infarction.